Next Generation News and Research

RSS

Clinical findings from Transgenomic's NuclearMitome Test study on nuclear mitochondrial disorders

Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic's NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina.

31 Mar 2012

NanoString to launch 3 new products for nCounter Analysis System at AACR 2012

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it will launch three new products for the nCounter Analysis System at the American Association of Cancer Research (AACR) Annual Meeting 2012, March 31-April 4, in Chicago, Ill.

From NanoString Technologies 31 Mar 2012

State of Texas awards Asuragen $6.8M to pursue Next Generation Sequencing applications

Asuragen, Inc. announced today that the Company received notice of a $6.8 million commercialization award to pursue Next Generation Sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas ("CPRIT").

31 Mar 2012

Cortex reports net income of $832,000 for fourth quarter 2011

Cortex Pharmaceuticals, Inc. reported net income of approximately $832,000, or $0.01 per share, for the quarter ended December 31, 2011, compared with a net loss of approximately $984,000, or $0.01 per share, for the corresponding prior year quarter.

31 Mar 2012

ChemoCentryx fourth quarter revenues increase to $26.1 million

ChemoCentryx, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2011.

31 Mar 2012

MO BIO introduces PowerMicrobiome RNA Isolation Kit

MO BIO Laboratories, Inc., the leader in soil, water and microbial nucleic acid purification, announces the launch of the PowerMicrobiome RNA Isolation Kit, the first kit available that is optimized for stool and gut material and provides high quality RNA for use in characterizing the human microbiome.

29 Mar 2012

Elekta receives EU CE marking for Connexion modular couchtop

Elekta's Connexion modular couchtop is CE marked and successfully released for sale in the European Union. Connexion meets the clinic's need to tailor patient set-up to accommodate the unique therapy requirements of the individual patient.

From Elekta 29 Mar 2012

Greenwood launches Syndromic Autism 62-Gene Panel

RainDance Technologies, Inc., the Digital Biology Company, today announced that Greenwood Genetic Center has commercially launched its Syndromic Autism 62-Gene Panel which was built for use on RainDance's picodroplet-based targeted sequencing platform.

29 Mar 2012

New McMaster centre to track health differences by ethnicity

Tracking health differences by ethnicity is the cornerstone of the new Chanchlani Research Centre at McMaster University.

29 Mar 2012

Affymetrix' GeneChip technology incorporated into Lineagen's FirstStepDx genetic evaluation service

Affymetrix, Inc. and Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, today announced the companies have signed an agreement to incorporate Affymetrix' GeneChip technology into Lineagen's next-generation FirstStepDx, a genetic evaluation service for individuals with developmental delay (DD), intellectual disability (ID), and autism spectrum disorders (ASD).

29 Mar 2012

FDA clears BD MAX assay for detecting GBS DNA in Lim Broth cultures

BD announced today the U.S. Food and Drug Administration clearance of the BD MAX Group B Streptococcus (GBS) Assay and Clinical Laboratory Improvement Amendments (CLIA) moderate complexity test categorization on the second-generation BD MAX System.

From BD (Becton, Dickinson and Company) 29 Mar 2012

Researchers profile genetic changes in cancer with drug sensitivity

In the largest study of its kind, researchers have profiled genetic changes in cancer with drug sensitivity in order to develop a personalised approach to cancer treatments. The study is published in Nature on Thursday 29 March 2012.

29 Mar 2012

Strand Diagnostics to receive $30 million in funding from NantWorks

Strand Diagnostics, LLC, maker of the know error system, and NantWorks, LLC announced that they have entered into an agreement whereby Strand will receive up to $30 million in funding from NantWorks, LLC over the next 3 years.

29 Mar 2012

New biography on intuitive genius of CT

This new biography sheds light on a Nobel Laureate who changed the world as a result of his breakthrough in medical imaging CT scans in 1972. Godfrey Hounsfield: Intuitive Genius of CT explores his life through stories and recollections of his colleagues, family and friends.

28 Mar 2012

Pfizer to present data on ADCs at AACR 2012

Pfizer Oncology will present data from a variety of preclinical and clinical studies of Pfizer's early-stage compounds, including data from Pfizer's investigational antibody-drug conjugate (ADC) portfolio and research evaluating several molecules targeting novel pathways that play a crucial role in basic cellular functions, at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, IL, from March 31-April 4.

27 Mar 2012